- Home
- ITIC vs MIST Comparison
ITIC vs MIST Comparison
Compare ITIC & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- MIST
- Stock Information
- Founded
- ITIC 1972
- MIST 2003
- Country
- ITIC United States
- MIST Canada
- Employees
- ITIC N/A
- MIST N/A
- Industry
- ITIC Specialty Insurers
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- ITIC Finance
- MIST Health Care
- Exchange
- ITIC Nasdaq
- MIST Nasdaq
- Market Cap
- ITIC 437.8M
- MIST 53.9M
- IPO Year
- ITIC N/A
- MIST N/A
- Fundamental
- Price
- ITIC $234.99
- MIST $1.11
- Analyst Decision
- ITIC
- MIST Strong Buy
- Analyst Count
- ITIC 0
- MIST 2
- Target Price
- ITIC N/A
- MIST $9.50
- AVG Volume (30 Days)
- ITIC 11.2K
- MIST 1.6M
- Earning Date
- ITIC 05-08-2025
- MIST 05-20-2025
- Dividend Yield
- ITIC 6.66%
- MIST N/A
- EPS Growth
- ITIC 18.56
- MIST N/A
- EPS
- ITIC 15.69
- MIST N/A
- Revenue
- ITIC $261,183,000.00
- MIST N/A
- Revenue This Year
- ITIC N/A
- MIST N/A
- Revenue Next Year
- ITIC N/A
- MIST N/A
- P/E Ratio
- ITIC $15.27
- MIST N/A
- Revenue Growth
- ITIC 15.26
- MIST N/A
- 52 Week Low
- ITIC $146.41
- MIST $0.63
- 52 Week High
- ITIC $290.40
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- ITIC 51.16
- MIST 43.96
- Support Level
- ITIC $237.00
- MIST $1.28
- Resistance Level
- ITIC $245.45
- MIST $1.32
- Average True Range (ATR)
- ITIC 5.50
- MIST 0.12
- MACD
- ITIC 0.94
- MIST 0.02
- Stochastic Oscillator
- ITIC 52.22
- MIST 27.39
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).